Nature Communications (Dec 2022)
PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression
- Lufei Sui,
- Suming Wang,
- Debolina Ganguly,
- Tyler P. El Rayes,
- Cecilie Askeland,
- Astrid Børretzen,
- Danielle Sim,
- Ole Johan Halvorsen,
- Gøril Knutsvik,
- Jarle Arnes,
- Sura Aziz,
- Svein Haukaas,
- William D. Foulkes,
- Diane R. Bielenberg,
- Arturas Ziemys,
- Vivek Mittal,
- Rolf A. Brekken,
- Lars A. Akslen,
- Randolph S. Watnick
Affiliations
- Lufei Sui
- Vascular Biology Program, Boston Children’s Hospital
- Suming Wang
- Vascular Biology Program, Boston Children’s Hospital
- Debolina Ganguly
- Hamon Center for Therapeutic Oncology Research and Department of Surgery, UT Southwestern
- Tyler P. El Rayes
- Department of Cardiothoracic Surgery, Weill Cornell Medical College
- Cecilie Askeland
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen
- Astrid Børretzen
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen
- Danielle Sim
- Vascular Biology Program, Boston Children’s Hospital
- Ole Johan Halvorsen
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen
- Gøril Knutsvik
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen
- Jarle Arnes
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen
- Sura Aziz
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen
- Svein Haukaas
- Department of Urology, Haukeland University Hospital
- William D. Foulkes
- Cancer Axis, Lady Davis Institute for Medical Research, Jewish General Hospital
- Diane R. Bielenberg
- Vascular Biology Program, Boston Children’s Hospital
- Arturas Ziemys
- The program in Mathematics in Medicine, Houston Methodist Research Institute
- Vivek Mittal
- Department of Cardiothoracic Surgery, Weill Cornell Medical College
- Rolf A. Brekken
- Hamon Center for Therapeutic Oncology Research and Department of Surgery, UT Southwestern
- Lars A. Akslen
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen
- Randolph S. Watnick
- Vascular Biology Program, Boston Children’s Hospital
- DOI
- https://doi.org/10.1038/s41467-022-35649-9
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 19
Abstract
Tsp-1 in the tumor microenvironment is known to suppress tumor growth and progression. Here the authors show that PRSS2 represses Tsp-1 by binding to lipoprotein receptor-related protein 1 and suggest targeting PRSS2 mediated Tsp-1 repression as a potential therapeutic strategy.
